Diabetic kidney disease (DKD) is a serious complication of diabetes, affecting millions of people worldwide. Inflammation and oxidative stress are key contributors to the development and progression of DKD, making them potential targets for therapeutic interventions. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a promising class of drugs, with evidence demonstrating that they can improve renal outcomes in people with diabetes. However, the exact mechanism by which SGLT2i exert their renoprotective effects is not yet fully understood. This study demonstrates that dapagliflozin treatment attenuates renal injury observed in type 2 diabetic mice. This is evidenced by the reduction in renal hypertrophy and proteinuria. Furthermore, dapagliflozin decreases tubulointerstitial fibrosis and glomerulosclerosis by mitigating the generation of reactive oxygen species and inflammation, which are activated through the production of CYP4A-induced 20-HETE. Our findings provide insights onto a novel mechanistic pathway by which SGLT2i exerts their renoprotective effects. Overall, and to our knowledge, the study provides critical insights into the pathophysiology of DKD and represents an important step towards improving outcomes for people with this devastating condition.
The rapid advancement of artificial intelligence, particularly large language models like ChatGPT-3.5, presents promising applications in healthcare. This study evaluates ChatGPT-3.5’s validity in responding to post-operative patient inquiries following surgery for benign prostatic hyperplasia (BPH). Common patient-generated questions were sourced from discharge instructions, online forums, and social media, covering various BPH surgical modalities. ChatGPT-3.5 responses were assessed by two senior urology residents using pre-defined criteria, with discrepancies resolved by a third reviewer. A total of 496 responses were reviewed, with 280 excluded. Among the 216 graded responses, 78.2% were comprehensive and correct, 9.3% were incomplete or partially correct, 10.2% contained a mix of accurate and inaccurate information, and 2.3% were entirely incorrect. Newer procedures (Aquablation, Rezum, iTIND) had a higher percentage of correct answers compared to traditional techniques (TURP, simple prostatectomy). The most common errors involved missing context or incorrect details (36.6%). These findings suggest that ChatGPT-3.5 has potential in providing accurate post-operative guidance for BPH patients. However, concerns regarding incomplete and misleading responses highlight the need for further refinement to improve AI-generated medical advice and ensure patient safety. Future research should focus on enhancing AI reliability in clinical applications.
Diabetic cardiomyopathy (DCM) is a major complication of type 2 diabetes mellitus (T2DM) that leads to significant morbidity and mortality. The alteration in the signaling mechanism in diabetes leading to cardiomyopathy remains unclear. The purpose of this study is to investigate the role of tauopathy in myocardial dysfunction observed in T2DM. In that regard, diabetic Sprague Dawley rats were treated with intraperitoneal injections of lithium chloride (LiCl), inhibiting tau phosphorylation. Cardiac function was evaluated, and molecular markers of myocardial fibrosis and the TGF-β signaling were analyzed. T2DM rats exhibited a decline in ejection fraction and fractional shortening that revealed cardiac function abnormalities and increased myocardial fibrosis. These changes were associated with tau hyperphosphorylation. Treating diabetic rats with LiCl attenuated cardiac fibrosis and improved myocardial function. Inhibition of GSK-3β leads to the suppression of tau phosphorylation, which is associated with a decrease in TGF-β expression and regulation of the pro-inflammatory markers, suggesting that tau hyperphosphorylation is parallelly associated with fibrosis and inflammation in the diabetic heart. Our findings provide evidence of a possible role of tau hyperphosphorylation in the pathogenesis of DCM through the activation of TGF-β and by inducing inflammation. Targeting the inhibition of tau phosphorylation may offer novel therapeutic approaches to reduce DCM burden in T2DM patients.
1 August 2026 in Urologic Oncology: Seminars and Original Investigations